Patients' experiences with decisions on timing of chemotherapy for breast cancer

Ligt, K.M. de; Spronk, P.E.R.; Bommel, A.C.M. van; Peeters, Marie‐Jeanne T. F. D. Vrancken; Siesling, Sabine; Smorenburg, Carolien H.

doi:10.1016/j.breast.2017.10.016

Cited by 10 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hahlweg et al analyzed 249 cases in 11 different cancer-specific MDT meetings and found that in 10% of cases more than one treatment recommendation was reported and this is comparable with our findings [ 17 ]. Explicit reporting the preferable timing of systemic therapy for early breast cancer, i.e., preoperative versus adjuvant, is done in only a small number of patients [ 19 ]. For IBR, it has already been shown that patients feel significantly more involved in shared decision-making if they are informed about the treatment alternatives [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical decision trees support systematic evaluation of multidisciplinary team recommendations

Hendriks

Verbeek

Manen

et al. 2020

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose EUSOMA's recommendation that "each patient has to be fully informed about each step in the diagnostic and therapeutic pathway" could be supported by guideline-based clinical decision trees (CDTs). The Dutch breast cancer guideline has been modeled into CDTs (www.oncog uide.nl). Prerequisites for adequate CDT usage are availability of necessary patient data at the time of decision-making and to consider all possible treatment alternatives provided in the CDT. Methods This retrospective single-center study evaluated 394 randomly selected female patients with non-metastatic breast cancer between 2012 and 2015. Four pivotal CDTs were selected. Two researchers analyzed patient records to determine to which degree patient data required per CDT were available at the time of multidisciplinary team (MDT) meeting and how often multiple alternatives were actually reported. Results The four selected CDTs were indication for magnetic resonance imaging (MRI) scan, preoperative and adjuvant systemic treatment, and immediate breast reconstruction. For 70%, 13%, 97% and 13% of patients, respectively, all necessary data were available. The two most frequent underreported data-items were "clinical M-stage" (87%) and "assessable mammography" (28%). Treatment alternatives were reported by MDTs in 32% of patients regarding primary treatment and in 28% regarding breast reconstruction. Conclusion Both the availability of data in patient records essential for guideline-based recommendations and the reporting of possible treatment alternatives of the investigated CDTs were low. To meet EUSOMA's requirements, information that is supposed to be implicitly known must be explicated by MDTs. Moreover, MDTs have to adhere to clear definitions of data-items in their reporting. Keywords Guidelines • Clinical decision trees • Decision support • Breast cancer • Multidisciplinary team Abbreviations AST Adjuvant systemic treatment CDT Clinical decision tree EUSOMA European Society of Breast Cancer Specialists IBR Immediate breast reconstruction MDT Multidisciplinary team MRI Magnetic resonance imaging PST Preoperative systemic treatment TNM Tumor (T), nodes (N) and metastases (M) Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical decision trees support systematic evaluation of multidisciplinary team recommendations

Hendriks

Verbeek

Manen

et al. 2020

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…In the USA, patient involvement was associated with a higher rate of mastectomy, which may largely be ascribed to the patients' risk perception. In the Netherlands, two recent studies of patient experiences regarding decisions on timing of chemotherapy and immediate breast reconstruction showed that not all patients were made aware of the possibilities of primary chemotherapy and immediate breast reconstruction. Although these studies did not address the choice of BCS or mastectomy, the results suggest that there is much to gain in terms of shared decision‐making.…”

Section: Discussionmentioning

confidence: 99%

Nationwide population-based study of trends and regional variation in breast-conserving treatment for breast cancer

Maaren

Strobbe

Koppert

et al. 2018

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…The authors do not necessarily advocate that every patient should receive NAC; however, every patient eligible to NAC should receive a choice in chemotherapy timing. Another work by our group describes how patients perceived the choice in chemotherapy timing [23].…”

Section: Practice Implicationsmentioning

confidence: 99%

Current decisions on neoadjuvant chemotherapy for early breast cancer: Experts’ experiences in the Netherlands

Spronk

Ligt

Bommel

et al. 2018

Patient Education and Counseling

Self Cite

View full text Add to dashboard Cite

Patients' experiences with decisions on timing of chemotherapy for breast cancer

Cited by 10 publications

References 24 publications

Clinical decision trees support systematic evaluation of multidisciplinary team recommendations

Clinical decision trees support systematic evaluation of multidisciplinary team recommendations

Nationwide population-based study of trends and regional variation in breast-conserving treatment for breast cancer

Current decisions on neoadjuvant chemotherapy for early breast cancer: Experts’ experiences in the Netherlands

Contact Info

Product

Resources

About